CD274 and cancer: Due to systemic side effects caused by type I interferons, strategies that induce type I interferon signaling have been explored as immunotherapy combination partners, including small molecule inhibitors or agonists [45, 46], cryoablation [44] and radiation therapy [47], and these studies revealed promising synergistic effect of these strategies with anti-PD-1/anti-PD-L1 therapy in cancer treatment.